22nd Hundred years initiates enrollment in Stage II-B clinical trial of X-22 for smoking cessation 22nd Hundred years Group, Inc. , a ongoing company focused on cigarette smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the initial patients in its Stage II-B clinical trial for X-22, a prescription cigarette smoking cessation assist in development. X-22 includes a kit of suprisingly low nicotine cigarettes created from 22nd Century’s proprietary tobacco.S. A lot more than 200 smokers will be enrolled in the multicenter Phase II-B clinical trial by the finish of August 2011. Primary endpoint results of the study, four weeks of continuous abstinence from smoking, november 2011 are expected to be accessible in late.The 940nm diode laser beam was found to possess higher efficacy for deeper blood vessels based upon its excellent penetration of the dermis with an extended wavelength. Furthermore, the 940nm wavelength corresponds with a lesser absorption peak of oxyhemoglobin than that for 532 nm, leading to slower and even more uniform heating system of the vessel, said lead author Emily Tierney, MD, an assistant professor of dermatology at BUSM. Furthermore, there is definitely minimal melanin absorption at the 940nm wavelength, and thus, there is less risk of post-inflammatory scarring or transformation, she added.